CVS Health thriving despite COVID setback

After weathering rising costs in its health insurance business due to claims coming in from rescheduled procedures, CVS Health expects excellent 2020 earnings on the strength of its diversified business model.

The company announced the upbeat outlook Wednesday, saying its second-quarter profits had exceeded Wall Street’s expectations.

In an interview with CNBC, the company’s CEO, Larry Merlo, said the pandemic “has really accelerated our transformation. We’ve got real-life examples of care being delivered in the community, in the home and in the palm of your hand as a result of what we’re dealing with in COVID-19.”

Asked if he believes the company—and the U.S. as a whole—are ready for a warned-of second COVID wave later this year, Merlo replied:

“As a country we’re testing about 17 million Americans a month. The experts say that, as we move into the fall, we’re going to need between 26 and 28 million tests on a monthly basis to meet the demand. One of the things we’re working on is creating a plan with which we can pivot to more point-of-care testing. More of those devices are being approved, and that’s something we expect to be able to do as we approach the fall timeframe to meet that increased demand.”

Click here for the written CNBC coverage and scroll to the bottom for the 8-minute interview.

Dave Pearson

Dave P. has worked in journalism, marketing and public relations for more than 30 years, frequently concentrating on hospitals, healthcare technology and Catholic communications. He has also specialized in fundraising communications, ghostwriting for CEOs of local, national and global charities, nonprofits and foundations.

Around the web

A string of executive orders from the White House created serious concerns among radiologists and other healthcare providers throughout the United States. The American College of Radiology issued a statement to help guide its members through the chaos. 

Bridgefield Capital, founded in 2015, has previously invested in such popular brands as Cirque Du Soleil, Del Monte and Quiksilver. This transaction is expected to be completed in the second half of 2025. 

Given the precarious excitement of the moment—or is it exciting precarity?—policymakers and healthcare leaders must set directives guiding not only what to do with AI but also when to do it.